Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study in Italy found that APS-1, a rare disorder, is associated with various AIRE gene mutations and most individuals have autoantibodies such as IFNωAbs, which are markers of the condition.

This study found that in AGA, the risk allele at locus 2q35 alters WNT10A expression through EBF1, suggesting a potential androgen-dependent regulatory mechanism.

This study found that CARI ONE, a herbal mixture, promotes hair growth in mice by inducing the transition from telogen to anagen phase and enhancing hair follicle development, compared to control and minoxidil treatments.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

In this study, researchers observed that dysregulated innate lymphoid cells type 1, alongside CD8+ T cells, may contribute to the pathogenesis of alopecia areata by affecting hair follicle health.

This study found an increased number of perivascular mast cells and upregulated CB1 expression in patients with IgA vasculitis compared to healthy individuals, suggesting potential involvement in the disease's pathogenesis and inflammation.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, suggesting that these cells might be a therapeutic target in AA management.

The study suggests that integrin β1 is crucial for maintaining liver microstructure and its absence may promote fibrosis by disrupting hepatocyte-extracellular matrix interactions and increasing TGF-β secretion.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

This study found that β1 integrin expression may serve as an indicator of androgenetic alopecia severity and could be involved in the disease's development.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.

CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

This study found that a specific fragment of AIMP1, secreted by hair follicle stem cells, activated dermal papilla cells, leading to enhanced hair regrowth and maintenance in mice.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.